Schizophrenia Research
Volume 71, Issue 1 , Pages 61-64 , 1 November 2004

Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample

Received 20 October 2003 ,Revised 23 December 2003 ,Accepted 12 January 2004.

References 

  1. Addington J, Addington D. Impact of an early psychosis program on substance use. Psychiatr. Rehabil. J. 2001;25:60–67
  2. Cantwell R, Brewin J, Glazebrook C, Dalkin T, Fox R, Medley I, et al. Prevalence of substance misuse in first-episode psychosis. Br. J. Psychiatry. 1999;174:150–153
  3. Dervaux A, Laqueille X, Bourdel MC, Leborgne MH, Olie JP, Loo H, et al. Cannabis and schizophrenia: demographic and clinical correlates. Encephale. 2003;29:11–17
  4. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). New York, NY: New York State Psychiatric Institute, Biometrics Research; 1995;
  5. Hambrecht M, Häfner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust. N. Z. J. Psychiatry. 2000;34:468–475
  6. Horan WP, Blanchard JJ. Neurocognitive, social, and emotional dysfunction in deficit syndrome schizophrenia. Schizophr. Res. 2003;65:125–137
  7. Joyal CC, Hallé P, Lapierre D, Hodgins S. Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophr. Res. 2003;63:297–299
  8. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  9. Kirkpatrick B, Amador XF, Flaum M, Yale SA, Gorman JM, Carpenter WT, et al. The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug use. Schizophr. Res. 1996;20:69–77
  10. Kirkpatrick B, Messias EM, Tek C. Substance abuse and the heterogeneity of schizophrenia: a population-based study. Schizophr. Res. 2003;62:293–294
  11. Lysaker P, Bell M, Beam-Goulet J, Milstein R. Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. J. Nerv. Ment. Dis. 1994;182:109–112
  12. Mueser KT, Bellack AS, Blanchard JJ. Comorbidity of schizophrenia and substance abuse: implications for treatment. J. Consult. Clin. Psychol. 1992;60:845–856
  13. Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict. Behav. 1998;23:717–734
  14. Mueser KT, Yarnold PR, Rosenberg SD, Swett C, Miles KM, Hill D. Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups. Schizophr. Bull. 2000;26:179–192
  15. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA. 1990;264:2511–2518
  16. Salyers MP, Mueser KT. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr. Res. 2001;48:109–123
  17. Scheller-Gilkey G, Thomas SM, Woolwine BJ, Miller AH. Increased early life stress and depressive symptoms in patients with comorbid substance abuse and schizophrenia. Schizophr. Bull. 2002;28:223–231
  18. Strakowski SM, Tohen M, Stoll AL, Faedda GL, Mayer PV, Kolbrener ML, et al. Comorbidity in psychosis at first hospitalization. Am. J. Psychiatry. 1993;150:752–757

PII: S0920-9964(04)00035-0

doi: 10.1016/j.schres.2004.01.005

Schizophrenia Research
Volume 71, Issue 1 , Pages 61-64 , 1 November 2004

Article Tools